{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:14:55Z","timestamp":1793070895761,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejca.2025.116100","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:24:47Z","timestamp":1762388687000},"page":"116100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Incidence, prevalence and treatment of patients with Epithelioid Haemangioendothelioma (EHE) in Canada: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) and Multi-pronged Canadian Research in Epithelioid Haemangioendothelioma (PRO_CARE EHE) study"],"prefix":"10.1016","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4823-7392","authenticated-orcid":false,"given":"Catherine S.","family":"Weadick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Alshibany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Jude","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3089-2006","authenticated-orcid":false,"given":"Caroline","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0281-5866","authenticated-orcid":false,"given":"Christopher","family":"Lemieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4746-3096","authenticated-orcid":false,"given":"Nikol","family":"Kuleshov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusra","family":"Kassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Styves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5914-9885","authenticated-orcid":false,"given":"Evonne","family":"Henning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Werier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Noujaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0825-5070","authenticated-orcid":false,"given":"Abha A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit Peretz","family":"Soroka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albiruni Abdul","family":"Razak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2025.116100_bib1","first-page":"259","article-title":"Epithelioid Hemangioendothelioma: an overview and update on a rare vascular tumor","volume":"8","author":"Sardaro","year":"2014","journal-title":"Oncol Rev"},{"issue":"2","key":"10.1016\/j.ejca.2025.116100_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246958","article-title":"Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network","volume":"16","author":"de Pinieux","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2025.116100_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2349991","article-title":"Epithelioid Hemangioendothelioma: incidence, mortality, prognostic factors, and survival analysis using the surveillance, epidemiology, and end results database","volume":"2022","author":"Liu","year":"2022","journal-title":"J Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2025.116100_bib4","doi-asserted-by":"crossref","first-page":"15101","DOI":"10.1002\/cam4.6181","article-title":"Incidence, demographics, and survival of malignant hemangioendothelioma in the United States","volume":"12","author":"Paulson","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2025.116100_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113262","article-title":"Epithelioid Hemangioendothelioma (EHE) in NETSARC: the nationwide series of 267 patients over 12 years","volume":"192","author":"Blay","year":"2023","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.ejca.2025.116100_bib6","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1002\/cncr.33618","article-title":"Ultra-rare sarcomas: A consensus paper from the connective tissue oncology society community of experts on the incidence threshold and the list of entities","volume":"127","author":"Stacchiotti","year":"2021","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2025.116100_bib7","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1378\/chest.11-0039","article-title":"Clinical patterns and outcome in Epithelioid Hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer","volume":"140","author":"Lau","year":"2011","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.ejca.2025.116100_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29882","article-title":"Epithelioid Hemangioendothelioma in children: The European pediatric soft tissue sarcoma study group experience","volume":"69","author":"Orbach","year":"2022","journal-title":"Pedia Blood Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2025.116100_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41379-019-0368-8","article-title":"Prognostic stratification of clinical and molecular Epithelioid Hemangioendothelioma subsets","volume":"33","author":"Rosenbaum","year":"2020","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.ejca.2025.116100_bib10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/gcc.20886","article-title":"A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in Epithelioid Hemangioendothelioma of different anatomic sites","volume":"50","author":"Errani","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2025.116100_bib11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/gcc.22073","article-title":"Novel YAP1-TFE3 fusion defines a distinct subset of Epithelioid Hemangioendothelioma","volume":"52","author":"Antonescu","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2025.116100_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/gcc.22839","article-title":"Variant WWTR1 gene fusions in Epithelioid Hemangioendothelioma-a genetic subset associated with cardiac involvement","volume":"59","author":"Suurmeijer","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2025.116100_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100170","article-title":"Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts","volume":"6","author":"Stacchiotti","year":"2021","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.ejca.2025.116100_bib14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ejrad.2006.03.022","article-title":"The lollipop sign: a new cross-sectional sign of hepatic Epithelioid Hemangioendothelioma","volume":"59","author":"Alomari","year":"2006","journal-title":"Eur J Radio"},{"issue":"9","key":"10.1016\/j.ejca.2025.116100_bib15","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.21873\/anticanres.13675","article-title":"The role of local therapy in multi-focal Epithelioid Haemangioendothelioma","volume":"39","author":"Tong","year":"2019","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2025.116100_bib16","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/01.blo.0000533623.60399.1b","article-title":"Soft Tissue Sarcoma of the Extremities: What Is the Value of Treating at High-volume Centers?","volume":"477","author":"Lazarides","year":"2019","journal-title":"Clin Orthop Relat Res"},{"issue":"5","key":"10.1016\/j.ejca.2025.116100_bib17","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/jso.24979","article-title":"Primary liver sarcomas in the modern era: resection or transplantation?","volume":"117","author":"Konstantinidis","year":"2018","journal-title":"J Surg Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.116100_bib18","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/cncr.22225","article-title":"Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy","volume":"107","author":"Mehrabi","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2025.116100_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cncr.33247","article-title":"Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian Rare Cancer Network","volume":"127","author":"Stacchiotti","year":"2021","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2025.116100_bib20","doi-asserted-by":"crossref","first-page":"e826","DOI":"10.1097\/MPH.0000000000001643","article-title":"A retrospective review of the use of sirolimus for pediatric patients with Epithelioid Hemangioendothelioma","volume":"42","author":"Engel","year":"2020","journal-title":"J Pedia Hematol Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.116100_bib21","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cam4.3807","article-title":"Systemic therapies in advanced Epithelioid Haemangioendothelioma: a retrospective international case series from the World Sarcoma Network and a review of literature","volume":"10","author":"Frezza","year":"2021","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.116100_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","article-title":"Pazopanib in advanced vascular sarcomas: an EORTC soft tissue and bone sarcoma group (STBSG) retrospective analysis","volume":"56","author":"Koll\u00e1r","year":"2017","journal-title":"Acta Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2025.116100_bib23","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-23-3817","article-title":"A single-arm phase 2 trial of trametinib in patients with locally advanced or metastatic Epithelioid Hemangioendothelioma","volume":"30","author":"Schuetze","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6_ement","key":"10.1016\/j.ejca.2025.116100_bib24","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1158\/1538-7445.AM2024-7280","article-title":"Abstract 7280: potential activity of TEAD inhibitor in Hippo-altered cancer including NF2 mutant solid cancer and TAZ-CAMTA1 fusion-driven Epithelioid Hemangioendothelioma (EHE)","volume":"84","author":"Byun","year":"2024","journal-title":"Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2025.116100_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3168","article-title":"A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors","volume":"40","author":"Tolcher","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2025.116100_bib26","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/TP.0000000000002982","article-title":"Liver transplantation for hepatic Epithelioid Hemangioendothelioma is facilitated by exception points with acceptable long-term outcomes","volume":"104","author":"Brahmbhatt","year":"2020","journal-title":"Transplantation"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:31:33Z","timestamp":1773315093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925009864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":26,"alternative-id":["S0959804925009864"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116100","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence, prevalence and treatment of patients with Epithelioid Haemangioendothelioma (EHE) in Canada: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) and Multi-pronged Canadian Research in Epithelioid Haemangioendothelioma (PRO_CARE EHE) study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116100"}}